HRP20170263T2 - LIJEČENJE ARTERIJSKE STJENKE KOMBINACIJOM RAAS INHIBITORA I HMG-CoA REDUKTAZE - Google Patents

LIJEČENJE ARTERIJSKE STJENKE KOMBINACIJOM RAAS INHIBITORA I HMG-CoA REDUKTAZE

Info

Publication number
HRP20170263T2
HRP20170263T2 HRP20170263TT HRP20170263T HRP20170263T2 HR P20170263 T2 HRP20170263 T2 HR P20170263T2 HR P20170263T T HRP20170263T T HR P20170263TT HR P20170263 T HRP20170263 T HR P20170263T HR P20170263 T2 HRP20170263 T2 HR P20170263T2
Authority
HR
Croatia
Prior art keywords
hmg
combination
coa reductase
arterial wall
wall treatment
Prior art date
Application number
HRP20170263TT
Other languages
English (en)
Inventor
Miso Sabovic
Original Assignee
Ims Medical D.O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ims Medical D.O.O. filed Critical Ims Medical D.O.O.
Publication of HRP20170263T1 publication Critical patent/HRP20170263T1/hr
Publication of HRP20170263T2 publication Critical patent/HRP20170263T2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20170263TT 2011-12-09 2012-12-07 LIJEČENJE ARTERIJSKE STJENKE KOMBINACIJOM RAAS INHIBITORA I HMG-CoA REDUKTAZE HRP20170263T2 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SI201100459 2011-12-09
SI201200268 2012-08-27
EP12798615.6A EP2787993B1 (en) 2011-12-09 2012-12-07 TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
PCT/EP2012/005074 WO2013083286A1 (en) 2011-12-09 2012-12-07 TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR

Publications (2)

Publication Number Publication Date
HRP20170263T1 HRP20170263T1 (hr) 2017-04-21
HRP20170263T2 true HRP20170263T2 (hr) 2018-12-28

Family

ID=47326055

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170263TT HRP20170263T2 (hr) 2011-12-09 2012-12-07 LIJEČENJE ARTERIJSKE STJENKE KOMBINACIJOM RAAS INHIBITORA I HMG-CoA REDUKTAZE

Country Status (6)

Country Link
US (1) US9498464B2 (hr)
EP (1) EP2787993B1 (hr)
ES (1) ES2622893T3 (hr)
HR (1) HRP20170263T2 (hr)
SI (1) SI2787993T1 (hr)
WO (1) WO2013083286A1 (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2911659A2 (en) * 2012-10-24 2015-09-02 Biocopea Limited Drug combinations and uses
JP6053945B2 (ja) * 2012-11-23 2016-12-27 ペキン ユニバーシティ サード ホスピタルＰｅｋｉｎｇ Ｕｎｉｖｅｒｓｉｔｙ Ｔｈｉｒｄ Ｈｏｓｐｉｔａｌ 肥満症、糖尿病、高血圧症及び高脂血症を治療するための局所薬としてのスタチン化合物の使用
EP3290022B1 (en) * 2016-09-01 2020-04-01 Peking University Third Hospital Use of statins in the treatment of ischemic diseases
CN113906518A (zh) * 2019-05-02 2022-01-07 闭环医药有限公司 用于向患者提供个性化医疗的方法和系统
US20230317230A1 (en) * 2019-05-02 2023-10-05 Closed Loop Medicine Ltd. Method for treating obesity
US12597496B2 (en) 2023-06-05 2026-04-07 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs
US12420014B2 (en) 2023-06-05 2025-09-23 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
DE10301371A1 (de) 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
HRP20050655A2 (en) * 2003-01-16 2006-05-31 Boehringer Ingelheim International Gmbh Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1871359A1 (en) * 2005-04-07 2008-01-02 Miso Sabovic Delaying the ageing process and disorders caused by ageing
US8642083B2 (en) * 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
KR20090114325A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 약제학적 제제
US20130338203A1 (en) * 2011-02-28 2013-12-19 Farmicom Pharmaceutical Company D.O.O. TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR

Also Published As

Publication number Publication date
EP2787993A1 (en) 2014-10-15
US20140323536A1 (en) 2014-10-30
US9498464B2 (en) 2016-11-22
SI2787993T1 (sl) 2017-04-26
EP2787993B1 (en) 2016-11-23
WO2013083286A1 (en) 2013-06-13
HRP20170263T1 (hr) 2017-04-21
ES2622893T3 (es) 2017-07-07

Similar Documents

Publication Publication Date Title
CY2022018I1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
SMT201600021B (it) Nuovi composti di chinolina sostituiti come inibitori della s-nitrosoglutatione reduttasi
HUS1900001I1 (hu) Transztiretin expressziójának módosítása
EP2533638A4 (en) NEW INHIBITORS OF S-NITROSOGLUTATHION REDUCTASE
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
EP2729806A4 (en) USE OF MARKED HSP90 INHIBITORS
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
AP3576A (en) Inhibitors of flaviviridae viruses
PL2552438T3 (pl) Sposoby leczenia raka wątrobowokomórkowego
HUE057925T2 (hu) Prolil hidroxiláz inhibitor kristályos alakjai
HRP20181695T1 (hr) Kristalni oblik inhibitora benzilbenzena sglt2
AP2012006413A0 (en) Inhibitors of flaviviridae viruses
EP2456440A4 (en) Quinolinone PDE2 INHIBITORS
WO2012092202A9 (en) Modulation of side effect profile of 5-alpha reductase inhibitor therapy
SMT201600001B (it) Imidazopiridazine come inibitori di akt chinasi
EP2824184A4 (en) MIRNA INHIBITOR
HRP20170263T2 (hr) LIJEČENJE ARTERIJSKE STJENKE KOMBINACIJOM RAAS INHIBITORA I HMG-CoA REDUKTAZE
LT2506840T (lt) Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
DK2533637T3 (da) Chromoninhibitorer af S-nitrosoglutathionreduktase
EP2563379A4 (en) SOX9 INHIBITORS
PT2608792T (pt) Métodos de administração de um inibidor de egfr
EP2772522A4 (en) Radical inhibitor
EP2755663A4 (en) MicroRNA Inhibitors
FR2955136B1 (fr) Arret de vantail